Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 74 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 74 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $196.08, for a total value of $14,509.92. Following the completion of the sale, the executive vice president owned 16,506 shares of the company’s stock, valued at approximately $3,236,496.48. This trade represents a 0.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Feld also recently made the following trade(s):

• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00.
• On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $186.01, for a total transaction of $10,602.57.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $196.11 on Monday. The firm has a market cap of $55.87 billion, a price-to-earnings ratio of 33.70, a price-to-earnings-growth ratio of 1.81 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company’s fifty day moving average is $190.37 and its 200-day moving average is $186.37. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Analysts Set New Price Targets

Several brokerages recently weighed in on BDX. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday, November 7th. Jefferies Financial Group upped their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Four research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $205.64.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Jump Financial LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth about $321,000. CreativeOne Wealth LLC lifted its holdings in shares of Becton, Dickinson and Company by 13.8% in the first quarter. CreativeOne Wealth LLC now owns 2,992 shares of the medical instruments supplier’s stock worth $685,000 after buying an additional 362 shares in the last quarter. WPG Advisers LLC purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $36,000. Finally, Vident Advisory LLC increased its stake in Becton, Dickinson and Company by 185.8% in the 1st quarter. Vident Advisory LLC now owns 11,082 shares of the medical instruments supplier’s stock worth $2,539,000 after acquiring an additional 7,204 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.